Trials / Completed
CompletedNCT00109265
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multicenter trial of single-agent treatment with OSI 774 in patients with histologically confirmed, incurable, locally advanced or metastatic breast cancer. Patients must have measurable disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib HCl (OSI-774) |
Timeline
- Start date
- 2001-05-01
- Completion
- 2002-10-01
- First posted
- 2005-04-26
- Last updated
- 2015-07-02
Source: ClinicalTrials.gov record NCT00109265. Inclusion in this directory is not an endorsement.